leucovorin + fluorouracil + oxaliplatin + cetuximab

This is a combination regimen consisting of four drugs: - **Leucovorin (folinic acid):** A vitamin B derivative that enhances the effectiveness and reduces the toxicity of fluorouracil. - **Fluorouracil (5-FU):** An antimetabolite chemotherapy agent that inhibits DNA synthesis by incorporating into DNA and RNA, leading to cell death. - **Oxaliplatin:** A platinum-based chemotherapeutic that forms crosslinks in DNA, inhibiting replication and transcription. - **Cetuximab:** A monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking downstream signaling pathways involved in tumor growth and survival. This combination is used primarily for advanced or metastatic colorectal cancer. The addition of cetuximab, an anti-EGFR targeted therapy, is typically reserved for patients with RAS wild-type tumors. The regimen combines cytotoxic chemotherapy with targeted therapy to improve response rates and survival outcomes in eligible patients.

Brand names

Erbitux (cetuximab)None for combination

Other names

FOLFOX4 + cetuximabFOLFOX-4 plus cetuximabFOLFOX4 plus cetuximabFOLFOX 4 plus cetuximab